Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management
Cureus · 16.11.2026
DOI: 10.7759/cureus.119798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 16.11.2026. Verfasst von Md Samim Shikari und 5 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Psoriasis is a chronic, immune-mediated inflammatory skin disease marked by complex interactions among genetic susceptibility, dysregulated cytokine signaling, keratinocyte activation, and systemic inflammation. Biologic therapies have transformed management by selectively targeting key inflammatory pathways, particularly tumor necrosis factor-alpha (TNF-α), IL-12/23, IL-17, and IL-23. This review aims to summarize the molecular basis, clinical efficacy, safety, treatment selection, and emerging personalization strategies associated with biologic therapy in psoriasis. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for relevant publications from 2016 to 2026, with selection based on predefined inclusion and exclusion criteria. Current evidence indicates that certain IL-17 and IL-23 inhibitors have demonstrated high rates of skin clearance in clinical trials, with differences in response onset and durability depending on the specific agent, patient population, and trial comparison, whereas TNF-α inhibitors retain value in selected patients, particularly those with psoriatic arthritis and established long-term response. Treatment choice is increasingly influenced by comorbidities, prior biologic exposure, infection risk, reproductive considerations, obesity, treatment persistence, and patient preference. Biomarkers, pharmacogenomics, therapeutic drug monitoring, multi-omic profiling, and artificial intelligence-based predictive models may further support individualized treatment selection, although these approaches remain largely investigational and are not sufficiently validated for routine biologic selection. Biologic therapy has substantially improved psoriasis outcomes, although long-term comparative safety, cost, accessibility, and validation of predictive tools remain important priorities for precision clinical management.
Zitieren
APA
Shikari, M. S., Gulati, S., Dasari, P., Kommana, J. S. S. V. P., Vasava, K. M., & Padmavathy, K. (2026). Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management. Cureus. https://doi.org/10.7759/cureus.119798
Vancouver
Shikari MS, Gulati S, Dasari P, Kommana JSSVP, Vasava KM, Padmavathy K. Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management. Cureus. 2026. doi:10.7759/cureus.119798
BibTeX
@article{Shikari2026,
author = {Shikari, Md Samim and Gulati, Sanjeev and Dasari, Prathyusha and Kommana, Jaya Sai Sankara Vara Prasad and Vasava, Kinjal M and Padmavathy, Karthika},
title = {Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.119798}
}
EUVIMED